tbuckley/cabot-search huggingface dataset:
WILLIAM CADOGAN (1711-1797)
Authors: 泰旦 深瀬
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Rapamycin inhibits the growth of cholangiocarcinoma cells in vitro
Authors: T. Sawada, T. Okada, K. Kubota
Journal: Journal of Clinical Oncology (2007)

15153 Background: In the present study, anti-neoplastic effect of rapamycin against cholangiocarcinoma was studied in vitro. Methods: Expression of mTOR in 4 cholangiocarcinoma cell lines, TFK1, HuCCT1, NOZW, and OZ was evaluated by real-time PCR. Then, the four cholangiocarcinoma cell lines were cultured with rapamycin (0, 25, 50, 100, 200 nM), gemcitabine (0, 0.5, 1, 2 μM), or both, and anti-proliferative effect was evaluated by MTT assay. Results: All the four cholangiocarcinoma cell lines expressed endogenous mTOR- mRNA. Level of expression was the highest in HuCCT1 (65.8), and the lowest in TFK1 (17.6). Then, rapamycin significantly inhibited the growth of all the four cholangiocarcinoma cell lines, in dose-dependent manner. Gemcitabine inhibited the growth of NOZW (48.4%) and HuCCT1 (48.9%), but less efficiently in TFK1 (5.9%) and OZ (27.4%). Furthermore, synergistic anti-proliferative effect of rapamycin and gemcitabine was observed in TFK1 (39.1%), NOZW (38.9%), and OZ (47.1%), not in HuCCT1 (18.9%). Conclusion: Rapamycin effectively inhibited the growth of the cholangiocarcinoma cell lines, and synergistic effect with gemcitabine was observed in three of the four cell lines. No significant financial relationships to disclose.
Pediatric Nursing: A Text-Book for Nurses.
Authors: Abraham Levinson
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16846: A Novel Strategy for Assessing Coronary In-stent Restenosis by Multi-Slice Computed Tomography Using Modified Contrast Density Evaluation Technique
Authors: Tomoko Nao, Toshiro Miura, Tatsuhiro Fujimura, Masayuki Yoshimura, Yoshiteru Nakashima, Takayuki Okada, Takayuki Okamura, Jutaro Yamada, Naofumi Matsunaga, Masunori Matsuzaki
Journal: Circulation (2010)

Background: A noninvasive evaluation of in-stent restenosis (ISR) is strongly desired because of the lower burden for the patients after PCI follow-up without cardiac catheterization. So far, there...
Abstract 5256: Identification of a Novel Epoxyeicosatrienoic Acid (EET) Receptor: EETs Function as Selective, Endogenous Thromboxane Receptor Antagonists
Authors: David J Behm, Andrea Ogbonna, Charlene Wu, Cynthia L Burns-Kurtis, Mark Pullen, Stephen A Douglas
Journal: Circulation (2008)

Introduction: Epoxyeicosatrienoic acids (EETs) are cytochrome P450 metabolites of arachidonic acid which elicit vasodilatory, anti-inflammatory and anti-thrombotic effects. Interestingly, however, the mechanism by which EETs function remains unclear and was therefore investigated in the present study. Since previous reports suggest EET mediated vasodilation is dependent on large-conductance Ca 2+ -activated K + (BK Ca ) and vanilloid transient receptor potential (TRPV4) channels, the ability of 14,15 EET to induce vasodilation was investigated in BK Ca and TRPV4 homozygous knockout mouse isolated aorta. Results: Contrasting previous reports, neither BK Ca nor TRPV4 gene deletion significantly altered the potency of 14,15 EET-induced reversal of tone established with the thromboxane receptor [TP] agonist U46619. Surprisingly, whereas 14,15 EET reversed U46619-contractile tone of rat isolated aorta (IC 50 1.2μM), the eicosanoid had no effect on either phenylephrine- or endothelin-1-contractile tone. The remaining three EET regioisomers (5,6 EET, 8,9 EET, 11,12 EET) acted similarly, suggesting EETs might function as TP antagonists. Consistent with competitive TP antagonism, 14,15 EET pretreatment (1–10μM) inhibited U46619-induced vasoconstriction in a concentration-dependent manner (pA 2 5.9). TP antagonism was observed in mouse and dog isolated arteries and rat tertiary bronchi, indicating that the effects are not specific to one species or tissue. Accordant with the functional potency at TP, 14,15 EET bound to recombinant human TP with a K i of 3.2μM. In contrast, 14,15 EET showed weaker affinities for other prostanoid receptors including DP, FP, EP 1–4 and IP (K i s 6.1, 5.3, 42.6, 19.7, 13.2, 20.2 and &gt;25μM, respectively) and no appreciable affinity (K i s &gt;10μM) for 51 “non-prostanoid” receptors/ion channels. Consistent with these data, 14,15 EET failed to inhibit (K b &gt;10μM) “non-TP” prostanoid receptor mediated function in multiple cell/tissue-based assays. Conclusions: EETs function as novel “endogenous” G-protein-coupled receptor competitive antagonists, inducing vasodilation via direct TP inhibition. Such observations might help develop novel strategies targeting the EET pathway for treatment of cardiovascular disease.
Global Association of Cold Spells and Adverse Health Effects: A Systematic Review and Meta-Analysis
Authors: Niilo R.I. Ryti, Yuming Guo, Jouni J.K. Jaakkola
Journal: Environmental Health Perspectives (2015)

There is substantial evidence that mortality increases in low temperatures. Less is known about the role of prolonged cold periods denoted as cold spells.We conducted the first systematic review and meta-analysis to summarize the evidence on the adverse health effects of cold spells in varying climates.Four databases (Ovid Medline, PubMed, Scopus, Web of Science) were searched for all years and languages available. "Cold spell" was defined as an event below a temperature threshold lasting for a minimum duration of 2 days. Of 1,527 identified articles, 26 satisfied our eligibility criteria for the systematic review, and 9 were eligible for meta-analyses. The articles were grouped by the three main study questions into Overall-effect Group, Added-effect Group, and Temperature-change-effect Group.Based on random-effects models in the meta-analyses, cold spells were associated with increased mortality from all or all nonaccidental causes (summary rate ratio = 1.10; 95% CI: 1.04, 1.17 based on 9 estimates from five studies), cardiovascular diseases (1.11; 95% CI: 1.03, 1.19; 12 estimates from eight studies), and respiratory diseases (1.21; 95% CI: 0.97, 1.51; 8 estimates from four studies). Estimated associations were stronger for people ≥ 65 years of age (1.06; 95% CI: 1.00, 1.12) than for people 0-64 years of age (1.01; 95% CI: 1.00, 1.03). Study-specific effect estimates from a limited number of studies suggested an increased morbidity related to cold spells, but it was not possible to quantitatively summarize the evidence.Cold spells are associated with increased mortality rates in populations around the world. The body of evidence suggests that cold spells also have other adverse health effects. There was substantial heterogeneity among the studies, which should be taken into account in the interpretation of the results.Ryti NR, Guo Y, Jaakkola JJ. 2016. Global association of cold spells and adverse health effects: a systematic review and meta-analysis. Environ Health Perspect 124:12-22; http://dx.doi.org/10.1289/ehp.1408104.
Endoscopic treatment of massive lower gastrointestinal bleeding related to appendiceal stump
Authors: Hamid Wani, A. Omosola, Shadi Mahmoud, Mohammad Butt, Saad Al Kaabi
Journal: Endoscopy (2015)

Massive lower gastrointestinal bleed from an appendiceal stump is rare. Most often bleeding is in the peritoneal cavity or the retroperitoneum, rarely in the cecum. To our knowledge, massive bleeding from an appendiceal stump occurring 3 weeks after laparoscopic appendectomy and successfully treated endoscopically has not been reported previously.
Epidemic Encephalitis (Encephalitis Lethargica).
Authors: Frederick Tilney, Hubert S. Howe
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pegylated liposomal doxorubicin in ovarian cancer patients with renal compromise
Authors: C. K. Basu, A. Mukhopadhyay, R. Pandey, S. Dey
Journal: Journal of Clinical Oncology (2009)

e16569 Background: Ovarian cancer patients with renal compromise poses problem in choosing chemotherapy for them. Pegylated liposomal doxorubicin (PLD) can be used in such cases. However there is not much data regarding the efficacy and toxicity of PLD. We used PLD in a few renal compromised ovarian and peritoneal cancer patients. Methods: The clinical records of patients with recurrent ovarian and peritoneal cancer patients with high creatinine or low creatinine clearance level who were given PLD at the Netaji Subhas Chandra Bose Cancer Research institute) (NCRI) from July 2005 to July 2008 was reviewed retrospectively to study efficacy and toxicity. Results: Twenty-one patients were identified, which included 16 with epithelial ovarian cancer, 5 with peritoneal cancer. Renal compromise was diagnosed and graded according to creatinine clearance test (CCT) as severe when less than 28 mL/min/1.5 m 2 , moderate when CCT is 28–55 mL/min/1.5 m 2 , and mild when CCT is 55–84 mL/min/1.5 m 2 . Normal value was taken as 85 mL/min/1.5 m 2 . Patients had distribution as mild: 4 patients, moderate:7 patients, and severe:10 patients. The initial doses of PLD were classified into regular initial dose (40 mg/m 2 /4 weeks) and lower initial dose (20–30 mg/m 2 /4 weeks). The median cycle was 5 (range 1–12). We used lower dose for moderate and severe renal disease. The incidence of palmar-plantar erythrodysesthesia 5/21 (23.8%), stomatitis 6/21(28.5%), and hematologic toxicity 3/21(14.2 %). Dose reduction due to toxicities occurred in 19.04 % (4/21) patients. Amongst 21 cases no patient had deterioration of renal function while and after the treatment with PLD. However we had primary treatment with PLD in four cases (2 moderate and 2 severe) while others had platinum based initial treatment. We did not have any complete responder though we had 6 (28.5%) partial responders, 8 (38.1%) stable diseases and 7(33.3%) progressive diseases. Conclusions: Patients with renal compromise who received PLD therapy at an initial dose lower than 40 mg/m 2 /4 weeks tolerated their treatment well. They required subsequent dose reduction due to mucocutaneous and cardiological toxicities in 19% cases. Treatment response in this population with ovarian and peritoneal cancer was similar to that of patients with normal renal function. No significant financial relationships to disclose.
Serum Diagnosis of Syphilis by Precipitation: Governing Principles, Procedure and Clinical Application of the Kahn Precipitation Test.
Authors: R. L. Kahn
Journal: JAMA (1925)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Modern Methods in the Diagnosis and Treatment of Heart Disease.
Authors: Francis Heatherley
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oxaliplatin and paclitaxel in inoperable cancer of the esophagus and the gastro-esophogeal junction: Results of a phase I/II study
Authors: V. Kaechele, T. Seufferlein, T. Höhler, M. Möhler, M. P. Lutz, G. Adler
Journal: Journal of Clinical Oncology (2005)

4229 Background: Oxaliplatin (L-OHP) and Paclitaxel (PCT) are active in squamous cell (SCC) and adeno carcinoma (AC) of the esophagus (E) and the gastro-esophogeal junction (GEJ); PCT in combination with cisplatin showed a promising activity in gastro-esophageal cancer. Concomitant administration of L-OHP and PCT in NSCLC is well tolerated and demonstrated activity. We examined tolerability and efficacy of the combination of L-OHP and PCT in patients with inoperable locally advanced or metastatic esophageal cancer. Methods: L-OHP 85mg/m2/2h and PCT 90mg/m2/3h were administered at days 1,15 & 29 (q d43). Pats received no chemotherapy within 6 months prior to the study. No prior therapy with any of the investigational drugs was allowed. Since Nov. 2002, 26 (23m/3f) pats with advanced or metastatic cancer of the E and the GEJ were enrolled. 22/26 pats (85%) presented in UICC IV. 21/26 pats were chemonaive. 9/13/2 pats had ECOG score 0/1/2, respectively. The median age was 56.5 (range 38–81) years. 20/6 pats had cancer of the E/GEJ, 17/3 of the esophageal cancers were SCC/AC. So far 16 (14m/2f) pats are evaluable for response and toxicity. Results: A median of 2 (range 0–5) cycles were given. Relevant grade 3/4 toxicities were neutropenia (12.5%) and neurotoxicity (6.3%). There was no therapy related toxic death. Neuropathy was observed in 12/16 pats and in all 11 pats receiving ≥ 2 cycles (8 pts grade 1). In one pat treatment was stopped due to neurotoxicity (grade 3) during the 5th cycle. In 26 of 41 cycles L-OHP and PCT were administed without delay. A dose reduction of 20% of L-OHP and PCT due to neutropenia was required in one pat. PR was observed and confirmed in 2 pats (12.5%). 7 pats had confirmed SD (44%) after 8 weeks. All 3 pats treated with with locally advanced, inoperable tumors had confirmed SD, however, there was no substantial downsizing of the tumor to enable potentially curative surgery. The median TTP for the evaluated patients was 4.0 months, the medium OS is not reached yet. Conclusions: L-OHP combined with PCT is a moderately active regimen with favourable toxicity in patients with locally advanced or metastatic cancer of the esophagus and the gastro-esophogeal junction. No significant financial relationships to disclose.
Breast screening
Authors: M. Rosen, N. Rehnqvist, M. Baum
Journal: BMJ (1999)

Editor—In a recent news article Mayor discusses a study whose results question the mammography screening recommendations of the National Board of Health and Welfare in Sweden.1

The Swedish study to which the article refers has many methodological limitations and fallacies and should not be considered seriously.2 Varying trends in the incidence of breast cancer among the county councils influence mortality trends, which was not taken into account by Sjonell and Stahle. Furthermore, they could not distinguish between the effects of the screening programme and those of “opportunistic screening.” They did not take account of the fact that the programmes started at different times in the county councils and were of different intensities or that a long follow up is needed to detect the effects of the programme. In addition, half of the study population was diagnosed with breast cancer before the screening programmes started. These patients obviously could not have benefited from the screening programme.

The main problem of the study is, however, the attention it has received from the mass media, which may create uncertainty among women about whether they should participate in the screening programme. Was it ethical to publish this study? This is a question primarily for the Swedish Medical Journal, which published the paper, but it is also an issue for the BMJ and others following the story. We believe that the article by Sjonell and Stahle would not have passed the scientific review process for an original article in the BMJ or other major peer reviewed journal.

We, as well as Sjonell and Stahle, are concerned about the ethical questions surrounding screening programmes and the need for evidence based recommendations for health policy programmes. This was one reason why the national board supported randomised controlled studies on mammography screening in Sweden. The national recommendations for mammography are based on these considerations and we see no reason to change them on the basis of such a defective study.
Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in Age-Related Macular Degeneration
Authors: Zohar Yehoshua, Carlos Alexandre de Amorim Garcia Filho, Renata Portella Nunes, Giovanni Gregori, Fernando M. Penha, Andrew A. Moshfeghi, Kang Zhang, SriniVas Sadda, William Feuer, Philip J. Rosenfeld
Journal: Ophthalmology (2013)
Aluminum and Renal Failure
Authors: M. E. De Broe, J. W. Coburn
Journal: Annals of Internal Medicine (1990)

General.- Historical survey of aluminum-related diseases.- Chemistry of aluminum.- The metabolism of aluminum.- Intestinal absorption of aluminum.- Aluminum determination in biological samples.- Quality control of aluminum measurements.- Pathophysiology.- Pathophysiologic mechanisms of aluminum toxicity: Aluminum-induced bone disease.- Aluminum encephalopathy: Experimental vs human.- Alzheimer's disease: Aluminum and fibrinous proteins.- Aluminum interaction with macromolecules and membranes.- Cellular and subcellular localization of aluminum: Histochemistry.- Cellular and subcellular localization of aluminum.- Experimental models of aluminum toxicity.- Clinical.- Sources of aluminum.- Unusual sources of aluminum.- Experimental aluminum induced bone disease.- Aluminum induced bone disease: Clinical features.- Aluminum induced bone disease: Histology.- Dialysis encephalopathy.- Other clinical syndromes associated with aluminum. Microcytic anemia, joint pain, severe infections, liver dysfunction.- Aluminum toxicity in childhood.- Occupational exposure to aluminum and its compounds and their health effects.- Diagnosis.- The Diagnosis of aluminum toxicity.- Treatment.- Deferoxamine therapy of aluminum toxicity in dialysis patients.- Alternative phosphate binders for aluminum hydroxide.- Risk factors for aluminum toxicity and its prevention.- Index of subjects.
Abstract 10900: Application of Normal Cutoff Values for Global Longitudinal Strain in Patients with Aortic Stenosis and Normal Ejection Fraction Identifies High Valvuloarterial Impedance but Not Symptoms
Authors: Adam T Coleman, Pantila Vanichakarn, Hayah M Kassis, Robert T Palac, Jeremiah R Brown, Bruce W Andrus, Salvatore P Costa, Timothy A Beaver
Journal: Circulation (2011)

Background: Prior studies have shown that global longitudinal strain (GLS) is reduced in patients with severe aortic stenosis (AS) and high valvuloarterial impedance (Zva) despite normal EF. There ...